Talbot Financial LLC Acquires 2,063 Shares of Johnson & Johnson (NYSE:JNJ)

Talbot Financial LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 91,459 shares of the company’s stock after purchasing an additional 2,063 shares during the quarter. Johnson & Johnson comprises approximately 1.9% of Talbot Financial LLC’s holdings, making the stock its 17th largest position. Talbot Financial LLC’s holdings in Johnson & Johnson were worth $14,468,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Miracle Mile Advisors LLC boosted its stake in Johnson & Johnson by 10.8% during the 1st quarter. Miracle Mile Advisors LLC now owns 65,280 shares of the company’s stock valued at $10,327,000 after purchasing an additional 6,383 shares during the period. Kowal Investment Group LLC raised its holdings in Johnson & Johnson by 25.2% in the 1st quarter. Kowal Investment Group LLC now owns 9,767 shares of the company’s stock valued at $1,545,000 after acquiring an additional 1,963 shares in the last quarter. Horizon Wealth Management LLC raised its holdings in Johnson & Johnson by 11.4% in the 1st quarter. Horizon Wealth Management LLC now owns 1,757 shares of the company’s stock valued at $278,000 after acquiring an additional 180 shares in the last quarter. BKM Wealth Management LLC raised its holdings in Johnson & Johnson by 16.3% in the 1st quarter. BKM Wealth Management LLC now owns 14,473 shares of the company’s stock valued at $2,289,000 after acquiring an additional 2,025 shares in the last quarter. Finally, Wolff Wiese Magana LLC raised its holdings in Johnson & Johnson by 8.0% in the 1st quarter. Wolff Wiese Magana LLC now owns 3,950 shares of the company’s stock valued at $625,000 after acquiring an additional 294 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on JNJ shares. Morgan Stanley cut their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America dropped their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Stock Down 0.3 %

Shares of JNJ opened at $146.03 on Wednesday. The firm has a market capitalization of $351.45 billion, a price-to-earnings ratio of 9.10, a PEG ratio of 2.43 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The business’s fifty day moving average price is $148.09 and its two-hundred day moving average price is $153.97. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period last year, the company earned $2.68 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.40%. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.